Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 13,473 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: cGVHD Clear all
Completed Phase 3 Interventional Results available

NVA237 BID Versus Placebo Twelve-week Efficacy Study

NCT01715298
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NVA237, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
59
States / cities
*See Various Dept.'s*, Arizona • Chandler, Arizona • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 23, 2026, 6:44 AM EDT
Not listed No phase listed Observational

Characterization of Adipose Derived Regenerative Cells (ADRCs) From Patients With Chronic Heart Disease

NCT02732106
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Not listed
Lead sponsor
Cytori Therapeutics
Industry
Eligibility
20 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
4
States / cities
La Jolla, California • Gainesville, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 23, 2026, 6:44 AM EDT
Active, not recruiting Not applicable Interventional

The GRoceries Aimed at Increasing Nutrition Study

NCT07167004
View directory record Official record
Conditions
Type 2 Diabetes, Type II Diabetes Mellitus, Type II Diabetes, Pre-diabetes, Pre-diabetic, Pre-diabetic State, Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes Mellitus, Type 2 Diabetes (T2DM)
Interventions
Marketing Nudges Only, Marketing Nudges + Dynamically Adapted Financial Incentives
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 70 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 6:44 AM EDT
Completed Phase 1 Interventional

COPE Intervention for Parents of Children With Epilepsy

NCT00767026
View directory record Official record
Conditions
Epilepsy
Interventions
COPE (Creating Opportunities for Parent Empowerment), Standard education
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 23, 2026, 6:44 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01054885
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF Inhalation Powder, FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
49
States / cities
Birmingham, Alabama • Jasper, Alabama • Lakewood, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 23, 2026, 6:44 AM EDT
Recruiting Phase 2 Interventional

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

NCT07219615
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 23, 2026, 6:44 AM EDT
Active, not recruiting Phase 1 Interventional

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

NCT02160015
View directory record Official record
Conditions
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Electrocardiogram, Ibrutinib, Lenalidomide, Magnetic Resonance Imaging, Rituximab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 6:44 AM EDT
Recruiting No phase listed Observational

Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease

NCT00092235
View directory record Official record
Conditions
Chronic Graft vs. Host Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 120 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 6:44 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

NCT02285062
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
lenalidomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, prednisone, vincristine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 80 Years
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
22
States / cities
Fayetteville, Arkansas • Orange, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 23, 2026, 6:44 AM EDT
Withdrawn Phase 2 Interventional

Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore)

NCT02766842
View directory record Official record
Conditions
Mesenchymal Tumor, Autoimmune Pancreatitis, Lymphoma, Solid Tumors
Interventions
EUS-FNB with ProCore needle, EUS-FNB with SharkCore needle, ProCore needle, SharkCore needle
Procedure · Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 23, 2026, 6:44 AM EDT
Recruiting Not applicable Interventional

National Program to Overcome Pelvic Pain studY (POPPY)

NCT06778070
View directory record Official record
Conditions
Chronic Pelvic Pain Syndrome (CPPS), Chronic Pelvic Pain Syndrome, Chronic Pelvic Pain
Interventions
Pelvic floor yoga, Physical conditioning
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 23, 2026, 6:44 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

NCT06850805
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps
Interventions
OPN-375, Placebo
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Huntsville, Alabama • Gilbert, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 23, 2026, 6:44 AM EDT
Completed Not applicable Interventional

Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases

NCT00376922
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Psychosocial Effects of Cancer and Its Treatment
Interventions
music therapy
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 23, 2026, 6:44 AM EDT
Completed Not applicable Interventional

Video vs. TTG Respiratory Inhaler Technique Assessment and InstructioN (V-TRaIN)

NCT02611531
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Asthma
Interventions
Video Module Education (VME), Teach-To-Goal (TTG)
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 23, 2026, 6:44 AM EDT
Recruiting Phase 3 Interventional

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

NCT06959095
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Depemokimab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
981 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
42
States / cities
Bakersfield, California • Modesto, California • Newport Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 6:44 AM EDT
Completed Not applicable Interventional Results available

Vector Engineering Clinical

NCT04725500
View directory record Official record
Conditions
COPD
Interventions
Auto-Titrating EPAP
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
40 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Youngstown, Ohio • Clairton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 23, 2026, 6:44 AM EDT
Completed Not applicable Interventional Results available

Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration

NCT05914311
View directory record Official record
Conditions
Chronic Pain
Interventions
Suture, Suture and Dermabond
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 23, 2026, 6:44 AM EDT
Active, not recruiting Not applicable Interventional

AeviceMD for Pediatric Asthma Management

NCT06321471
View directory record Official record
Conditions
Asthma, Asthma in Children, Pediatric Asthma, Chronic Respiratory Disease
Interventions
AeviceMD
Device
Lead sponsor
Irina Dralyuk
Other
Eligibility
3 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 23, 2026, 6:44 AM EDT
Not yet recruiting Not applicable Interventional

RUSH Food is Medicine Veggie Rx - GusNIP Produce Prescription

NCT07376044
View directory record Official record
Conditions
Food Insecurity, Diabetes in Adults, Hypertension (HTN)
Interventions
Food is Medicine
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 23, 2026, 6:44 AM EDT
Completed Phase 2 Interventional Results available

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

NCT00301834
View directory record Official record
Conditions
Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Leukemia, Myelodysplastic Syndromes, Severe Congenital Neutropenia
Interventions
alemtuzumab, busulfan, cyclosporine, fludarabine phosphate, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
San Francisco, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 23, 2026, 6:44 AM EDT
Not listed Phase 4 Interventional

Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

NCT03502031
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2
Interventions
Renin-Angiotensin (RAAS) alone, Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
Drug
Lead sponsor
James A. Tumlin, MD
Other
Eligibility
75 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Lawrenceville, Georgia • Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 23, 2026, 6:44 AM EDT
Completed Not applicable Interventional

Effects of Intradialytic Exercise as Assessed by Bioimpedance Analysis and Blood Volume Monitoring

NCT01273753
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Intradialytic exercise
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 23, 2026, 6:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers

NCT00777595
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
CHF 4226 pMDI, Placebo, Moxifloxacin
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Oct 23, 2026, 6:44 AM EDT
Completed Phase 1 Interventional Results available

Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients

NCT04981912
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions
HDMP + rituximab as a means of debulking prior to initiating venetoclax.
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 23, 2026, 6:44 AM EDT